Flow Cytometry Score of Ahlan et al for a Patient with Myelodysplastic Syndrome (MDS)

Description

Ahlan et al developed a simple prognostic score for patients with the myelodysplastic syndrome based on findings on flow cytometry. This can be helpful to identify patients with low risk IPSS scores who may have more aggressive disease.The authors are from VU University Medical Center in Amsterdam.

Patient selection: myelodysplastic syndrome

Analysis: flow cytometry of bone marrow aspirate

Parameters:

(1) sideward light scatter (SSC) of myeloid precursors as standard deviation relative to normal mean (Z score)

(2) CD117 expression of myeloid precursors as standard deviation relative to normal mean

(3) CD13 expression of monocytic cells as standard deviation relative to normal mean

Parameter	Findings	Points
sideway light scatter	> 0.8 SD below mean	0
	<= 0.8 SD below mean	1
CD117 expression	> 3.6 SD above mean	0
	<= 3.6 SD above mean	1
CD13 expression in monocytes	> 1.5 SD below mean	0
	<= 1.5 SD below mean	1

total score =

= SUM (points for all 3 parameters)

Interpretation:

• minimum score: 0

• maximum score: 3

• The higher the score the worse the prognosis.

Score	Risk Group	5-Year Overall Survival
0	low	85%
1	intermediate	60%
2 or 3	high	20%

To read more or access our algorithms and calculators, please log in or register.

Flow Cytometry Score of Ahlan et al for a Patient with Myelodysplastic Syndrome (MDS)

Description

Specialty